This program will inform clinicians of immunopathological assessment of melanoma especially in relation to patterns of resistance, the advantages of novel combination immunotherapies in the treatment of melanoma, and the evaluation of associated toxicities and their management in patients.

RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024